Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 6, 2026PLoS ONEOpen Access

Safety and therapeutic potential evaluation of Cefotaxime plus Polymyxin B against polymyxin-carbapenem resistant Klebsiella pneumoniae in a murine model

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMariana Carvalho SturaroNDNathalia da Silva DamacenoGSGleyce Hellen de Almeida de Souza

Discussion

Loading...

Member takes

Overview

Demonstrates antibacterial efficacy of Cefotaxime and Polymyxin B in mice, highlighting potential for treating resistant Klebsiella infections.

Key Points

  • Evaluate the toxicity and antibacterial efficacy of Cefotaxime/Polymyxin B against resistant Klebsiella pneumoniae.
  • Conducted a single-dose toxicity assay in BALB/c mice
  • Monitored body weight, food, and water intake for 14 days
  • Analyzed organ weights and plasma biochemical markers post-euthanasia
  • High doses of CTX maintained stable weight but caused elevated urea levels
  • CTX/PMB combination significantly reduced blood bacterial load
  • Improved clinical condition observed in CTX/PMB group compared to others

Cite This Study

Sturaro et al. (2026) studied this question.

synapsesocial.com/papers/695d856e3483e917927a51c5https://doi.org/10.1371/journal.pone.0339990
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Optimizing Polymyxin B Therapy in Critical Care: Pharmacokinetic Insights and Clinical Outcomes in a Retrospective Cohort Study2025
  2. 2The association between acute kidney injury and Polymyxin B treatment: A retrospective cohort study2025
  3. 3P103 VRP-034 at higher doses: a comprehensive preclinical evaluation of polymyxin B-associated nephrotoxicity across <i>in vitro</i> , <i>in vivo</i> and translational models2025
  4. 4Pharmacokinetics and Penetration of a Novel Pharmacodynamically Optimized, Carbapenem-Sparing Antibiotic, WCK 4282 (Cefepime/Tazobactam), into Epithelial Lining Fluid of Healthy, Lung-, and Thigh-Infected Neutropenic Mice2025
  5. 5Identification and preclinical efficacy evaluation of two lytic bacteriophages targeting highly virulent and multidrug-resistant Klebsiella pneumoniae2025